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Abstract
Antibiotic resistance presents a significant challenge to clinical, veterinary, and plant health and is 
now recognized by the World Health Organization (WHO) as a major emerging problem of global 
significance. As yet, there have been no successful discoveries of classes of novel antibiotics since 
1987. There is an antibiotic discovery void, and it is now widely acknowledged that there is an 
urgent need for the development of novel antimicrobial agents. For economic reasons, many of the 
largest pharmaceutical companies have abandoned the antibiotic field, and research conducted by 
academia was scaled back due to funding cuts following the economic crisis. A post-antibiotic era—
in which common infections and minor injuries can kill—far from being an apocalyptic fantasy, is 
indeed a very real possibility for the 21st century.
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Introduction
Since the discovery and introduction of antibiotic agents in the 
early 20th century, their targeted selective toxicity has ensured their 
widespread use to combat infections. The overuse of antibiotics has 
now resulted in the emergence of multidrug-resistant pathogens, 
due to the dispersal of antibiotics into the wider environment, 
often in sub-lethal concentrations. Antibiotic-resistant bacteria can 
be transmitted to humans through direct contact with livestock, 
through the food chain, and the wastewater from farms, hospitals, 
and pharmaceutical plants.
‘The antibiotic paradox’ describes the premise that this misuse 
of antibiotics destroys their curative powers. Antibiotic resistance 
now presents a significant challenge to clinical, veterinary, and plant 
health and is now recognized by the World Health Organization 
(WHO) as a major emerging problem of global significance. With 
some 80 per cent of the global human population reliant on trad-
itional medicines, much of which is based on plant remedies, 
global and local research is being undertaken into sourcing novel 
antimicrobials from native botanical and fungal floras for plant 
health and biomedical applications. Resources such as higher plants, 
marine, and terrestrial algae and fungi have not only been historic-
ally exploited, but are currently being scouted as potential sources of 
sustainable alternate natural complimentary therapies.
An Historical Perspective
For all the technological advances humanity has achieved over the 
preceding few millennia, one of the most important has been our 
ongoing war against the microbes that surround us in our daily lives. 
Infectious diseases can and do overwhelm and decimate human 
populations, as evidenced by the Spanish Flu which followed World 
War I from 1918 to 1920. This killed somewhere between 50 and 
100 million people globally, some 3%–5% of the world’s population 
(Taubenberger and Morens, 2006). Throughout humanity’s history 
of warfare, the overwhelming cause of death has not been wars or 
military campaigns, but infections, which were much more proficient 
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at killing than any military strategy. One of the reasons it was so 
easy for the relatively small Spanish army to subdue millions of 
people living in South America was the infections such as smallpox, 
measles, and cholera that came with the invaders (Bianchine and 
Russo, 1992). To date, humanity has only eradicated a single infec-
tious disease of humans, namely smallpox, caused by the variola 
virus (WHO, 1988). Writing in 1999, Iwu et al. stated that infectious 
diseases accounted for approximately 50 per cent of all deaths in 
tropical countries, and that infectious disease mortality rates were 
actually increasing in developed countries. The increase was attrib-
utable to HIV/AIDS and respiratory tract infections, together with 
an increase in antibiotic resistance in nosocomial and community-
acquired infections.
Long before mankind discovered the existence of microbes, our ‘war’ 
against them began with vaccination and the pioneering work of Edward 
Jenner in 1796, when he successfully used pus from cowpox blisters 
to induce immunity to smallpox. This work was published privately 
as a text in 1798 (Jenner, 1798). The contemporary understanding of 
vaccination is the introduction of an antigen (or vaccine) in order to 
stimulate an individual’s immune system and develop immunity to a 
pathogen via the production of antibodies. Jenner did not understand 
the close relationship of the two causative agents of cowpox and 
smallpox, now known to be viruses. The next stage in the develop-
ment of methods to control microbes came in the 1860s with Joseph 
Lister’s use of sterilization methods and his introduction of antiseptics. 
Lister pioneered the use of carbolic acid or phenol solution for the 
sterilization of surgical instruments and direct application to incisions 
and dressings, which helped turn hospitals from places of high mortality 
(Lister, 1867). Antiseptics are in common usage today, and all are 
antimicrobial substances applied directly to the skin or tissue to reduce 
the possibility of infection. Frequently used antiseptics include alcohol, 
hydrogen peroxide, iodine, and trichlorophenols (TCP). In 1871, 
Lister investigated the discovery that urine samples contaminated by 
moulds did not allow bacterial growth. This was one of the first studies 
investigating the basic principles of biocontrol and he named the mould 
responsible as Penicillium glaucum.
Within the last century came the first antibiotic, penicillin, 
discovered by Sir Alexander Fleming, who noted the inhibitory 
property of a Penicillium mould on disease causing staphylococci, 
in 1928 (Ackerknecht, 1982). This breakthrough was followed 
by the synthesis of the first sulphonamide drug, Prontosil, by the 
German biochemist Gerhard Domagk (Domagk, 1935). Prontosil 
was derived from a synthetic red dye. Its use resulted in a sharp 
decline in mortality from infections due to Gram-positive cocci, 
and Domagk was awarded the 1939 Nobel Prize in Physiology 
or Medicine. Antibiotics (antibacterials) are antimicrobial drugs 
used to treat or prevent bacterial infections, and are conveniently 
grouped according to their mechanism of action against bacteria as 
shown in Table 1. Today, antibiotics are used to treat or prevent bac-
terial infections in clinical and veterinary situations. Penicillin was 
developed for use against many bacterial infections, such as scarlet 
fever (Streptococcus). Following the purification of the first peni-
cillin by Florey and Chain, they went on to achieve purification and 
large-scale production of the first antibiotic, penicillin G, by 1942. 
Fleming, Florey, and Chain shared the Nobel Prize for Physiology 
and Medicine in 1945. Penicillin saved the lives of innumerable 
injured allied soldiers during World War II, as few microbes had been 
exposed to penicillin before encountering it, and the majority were 
susceptible to it at that time.
The term antibiotic was credited as being used by Waksman et al., 
in 1947, to include any substance produced by a microorganism 
that was antagonistic to the growth of other microorganisms in 
high dilution (Waksman, 1947). In 1944, Waksman and Schatz 
isolated streptomycin from Streptomyces griseus (Schatz et al., 1944). 
Clinically, the role of antibiotics has since expanded from treating ser-
ious infections, to preventing infection in surgical and cancer patients, 
and protecting individuals with compromised immune systems. 
Antibiotics have also been used in veterinary medicine since they be-
came widely available. An estimated 80 per cent of all antibiotics 
consumed in the USA are used in the feed of animals intended for 
human consumption [The Center for Disease Dynamics, Economics 
and Policy (CDDEP), 2015]. The selective pressures humanity thus 
placed upon microbial communities by the use of antimicrobials 
and antibiotics inevitably led to resistance, exactly as Sir Alexander 
Fleming forecast in an interview after winning the Nobel Prize in 
1945 for discovering penicillin: ‘The thoughtless person playing with 
penicillin treatment is morally responsible for the death of the man 
who succumbs to infection with the penicillin-resistant organism’.
Table 1. Antibiotic grouping by mechanism of action.
Mechanism Class of antibiotic Selected drug examples
Inhibitors of cell wall synthesis (beta-lactams) Penicillins Penicillin G, Methicillin, Ampicillin





Disruptors of cell membranes Polymyxins Polymyxin B, Polymyxin E
Nucleic acid synthesis inhibitors DNA synthesis inhibitors Nalidixic Acid, Ciprofloxacin
RNA polymerase inhibitors Rifampin
Protein synthesis inhibitors 30s subunit—aminoglycosides Gentamicin, Streptomycin
Tetracyclines Tetracycline, Doxycycline
50s subunit—macrolides Erythromycin, Clarithromycin
Chloramphenicol Chloramphenicol
Lincosamide Clindamycin
Folic acid synthesis inhibitors Sulfonamides/Trimethoprim Sulfamethoxazole, Trimethoprim
Pyrimethamine Pyrimethamine
Mycolic acid synthesis inhibitors Isoniazid Isoniazid
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Antimicrobial Resistance
Antimicrobial resistance (AMR) is a process in which a micro-
organism evolves to become either more, or fully resistant to an anti-
microbial agent which could previously treat it effectively. Antibiotic 
resistance, which applies specifically to bacteria and antibiotics in a 
clinical situation, refers to a microorganism’s resistance to an anti-
biotic, and is a direct result of antibiotic use. AMR is increasing, 
especially in the context of healthcare-associated infections (HAIs), 
or nosocomial infections, which are those acquired by hospital 
patients who were admitted for reasons other than that infection. 
Such patients have increased reliance on antibiotics, which in turn 
results in increased drug resistance among common, previously 
treatable HAIs (Choffness et al., 2011), hence the rise of organisms 
such as vancomycin-resistant enterococci (VRE) and methicillin-
resistant Staphylococcus aureus (MRSA). As hospitals and other 
long-term care facilities use large quantities of antibiotics, they 
can become reservoirs of resistant pathogens. Other significant 
issues associated with higher levels of AMR include the increased 
costs of treatment and raised patient mortality. The US Centers for 
Disease Control and Prevention (CDC) estimates that antibiotic 
resistance causes more than 2 million infections and some 23,000 
deaths each year in the USA of which 14 000 were attributable to 
Clostridium difficile in 2013. This organism is resistant to most 
antibiotics and can proliferate in the human intestine after the de-
mise of other antibiotic sensitive species. A further 25 000 deaths 
a year in Europe were attributed to antibiotic resistance in 2007, 
with an additional total extra healthcare cost and productivity loss 
of 1.5 billion Euro (The Bacterial Challenge, 2009). The dates of 
discovery and introduction of the classes of antibiotics, together 
with the year when antibiotic resistance to each was first noted, 
are presented in Table 2, and mechanisms of resistance in Table 3. 
Resistance due to decreasing antibiotic effectiveness has risen from 
a minor issue, to a global challenge, and it has been said that we 
now live in a ‘post-antibiotic era’. Keiji Fukuda (Assistant Director-
General, Health Security) stated in the Foreword that, ‘A post-
antibiotic era--in which common infections and minor injuries can 
kill--far from being an apocalyptic fantasy, is indeed a very real 
possibility for the 21st century’.
Table 2.  Dates of introduction of antibiotic classes and first observation of resistance.
Class of antibiotic Year of discovery/introduction Year resistance observed Activity or target species
Inhibitors of cell wall synthesis
 Penicillins 1928/1938 1945 Broad-spectrum
 Vancomycin 1953/1958 1960 Gram-positive bacteria
RNA polymerase inhibitors
 Rifampicin 1957/1958 1962 Gram-positive bacteria
DNA synthesis inhibitors    
 Ciprofloxacin 1961/1968 1968 Broad-spectrum
Protein synthesis inhibitors
 30s subunit—aminoglycosides    
  Streptomycin 1943/1946 1946 Broad-spectrum
  Tetracyclines 1944/1952 1950 Broad-spectrum
 50s subunit—macrolides    
  Chloramphenicol 1946/1948 1950 Broad-spectrum
  Streptogramin B 1963/1998 1964 Gram-positive bacteria
Table 3. Mechanisms of antibacterial resistance. 
Basis of resistance Mechanism Bacterial proteins/targets responsible Antibiotic targets




Enhanced efflux Active extrusion Membrane proteins All major antibiotics
Enzyme Hydrolysis Beta-Lactamases Beta-Lactams
Esterase Macrolide






Target modification Structural alterations/modifications Penicillin binding proteins Beta-Lactams
Cell wall precursors Vancomycin
Ribosomal subunits Streptomycin
Mutations in genes RNA polymerase Rifamycin
Amino acid substitutions DNA gyrase/topoisomerase Quinolones
Methylation 16S rRNA Aminoglycosides
Mutation 23S rRNA Oxazolidinones
Target protection Ribosome protection Ribosome protection proteins Tetracycline
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Antibacterial agents do however leave survivors resistant to 
that particular agent or antibiotic. Suddenly freed from so many 
competitors, these survivors reproduce quickly, spread, and colonize. 
Places associated with scrupulous hygiene, such as hospital wards and 
operating theatres, are particularly vulnerable. A survey of over 2000 
US hospitals in 2009–10 found that some 20 per cent of such hospital-
acquired infections involved multidrug-resistant organisms (the so-called 
‘superbugs’) (Sievert et al., 2013). By the production of biofilms, bac-
teria adopt a multicellular behaviour that can facilitate and/or prolong 
their survival in diverse environmental niches. In hospital settings, the 
formation of biofilms on vents and medical equipment enables bacteria 
such as Pseudomonas aeruginosa to persist as reservoirs that can readily 
spread to patients (Kostakioti et al., 2011).
Mechanisms of AMR
A significant milestone in our understanding of microbes and 
their role in infection was the discovery that microbial antibiotic 
resistance genes themselves are transmissible and promiscuous, so 
spreading from organism to organism. Bacterial resistance can come 
about for a number of reasons, classically due to a mutation of the 
antibiotic-target gene in the bacterial chromosome, or elsewhere 
following the addition of extra-chromosomal DNA (Ventola, 2015a 
and 2015b). However, resistance is most commonly associated with 
the acquisition of extra-chromosomal elements encoding resistance 
determinants. These elements are acquired from other bacteria 
in the environment in a number of ways. A  transformation event 
involves the incorporation of free DNA segments into the bacterial 
chromosome. Transduction involves gene transfer following infection 
by a defective bacteriophage. The most efficient process, and the one 
that has the greatest impact on the spread of antibiotic resistance, 
is via the transfer of plasmids and conjugative transposons during 
cell-to-cell contact during conjugation (Alekshun and Levy, 2007; 
Ventola, 2015a). The importance of Horizontal Gene Transfer via 
conjugation is highlighted in the following reports.
Blanco et al. (2016) report that bacterial multidrug efflux pumps 
are antibiotic resistance determinants present in all microorganisms: 
efflux pumps are ancient, highly conserved determinants, which have 
been selected long before the recent use of antibiotics for the therapy 
of human infections. The role of efflux pumps as relevant antibiotic 
resistance determinants in bacterial pathogens is likely secondary to 
other functional roles with reference to bacterial physiology (Blanco 
et  al., 2016). However, tetracycline resistance can be encoded by 
four different determinants residing on plasmids in Escherichia 
coli: plasmid RP1 (class A), plasmid R222 (class B), plasmid R144 
(class C), and plasmid RA1 (class D) (McMurry et al., 1980).
Shaikh et al. (2015) state that transferase enzymes are the most 
diverse family of resistant enzymes which inactivate antibiotics, 
including beta-lactams, aminoglycosides, chloramphenicol, and 
streptogramin A. The mechanism involves chemical substitution, i.e. 
the addition of chemical groups to the periphery of the antibiotic 
molecule, which impairs their binding to a target. Polymyxin 
antibiotic resistance normally involves chromosomal mutation, 
but an E.  coli strain, SHP45, possessing colistin resistance that 
could be transferred to a second strain by a plasmid, MCR-1, was 
isolated by Liu et al. (2016). Leclercq (2002) states that resistance to 
macrolide (erythromycin) and lincosamide (clindamycin) antibiotics 
is increasingly reported in clinical isolates of Gram-positive bacteria. 
There are considered to be three mechanisms of resistance: ribosomal 
modification, efflux of the antibiotic, and drug inactivation. Plasmid-
mediated resistance is not recorded. Resistance to trimethoprim and 
sulphonamides came about following horizontal spread of resistance 
genes, expressing drug-insensitive variants of the target enzymes 
(dihydropteroate synthase for sulphonamide and dihydrofolate 
reductase for trimethoprim). Two genes, sul1 and sul2 expressing 
dihydropteroate synthases highly resistant to sulphonamide, are 
carried by transposons and plasmids. Almost 20 different resistance 
genes expressing drug-insensitive dihydrofolate reductases are spread 
as cassettes in integrons, transposons, and plasmids (Sköld, 2001). 
Fluoroquinolone antibiotics (such as nalidixic acid and ciprofloxacin) 
are broad-spectrum agents used to treat a range of infections. They 
target DNA gyrase and topoisomerase enzymes which control 
DNA supercoiling within the cell. Various genes encoding different 
resistance mechanisms are often found on plasmids, and known 
as plasmid-mediated quinolone resistance (PMQR) genes, the first 
one being isolated from a plasmid in a clinical isolate of Klebsiella 
pneumoniae (Redgrave et  al., 2014). It can be seen that bacteria 
acquire antibiotic resistance genes most commonly by conjuga-
tion, whereby a resistant ‘donor’ strain can transfer a plasmid to 
an antibiotic-susceptible recipient in what is termed a horizontal 
exchange. Plasmids are extra-chromosomal loops of DNA that act 
as vectors which can carry and transfer antibiotics resistance genes. 
Such transfer can occur both within members of the same species 
and also between genera or species. One plasmid with a broad host 
range is the resistance plasmid RP1, first identified in a clinical strain 
of P. aeruginosa. This plasmid can transfer to most, if not all Gram-
negative bacteria (Bennett, 2009) and carries resistance to ampicillin, 
tetracycline, and kanamycin. Newly resistant cells can then transmit 
resistance vertically to daughter generations.
AMR bacteria constitute a threat to public health globally. From 
initially occurring in hospital settings, where organisms with low-
level antibiotic resistance were treated with larger antibiotic dosages, 
given time, highly resistant strains emerged, such as penicillin-resistant 
S.  aureus found in hospitals in the 1950s. Initially, the organisms 
isolated had a single antibiotic resistance, but Shigella dysenteriae 
resistant to tetracycline, chloramphenicol, streptomycin, and 
sulphonamides was isolated in the late 1950s (Levy, 1982). A notable 
example is resistance to penicillin among staphylococci, specified by 
the penicillinase enzyme, which degrades the antibiotic. So, after the 
surviving pathogenic bacteria adapted to their newly toxic human 
environment, resistance began to spread rapidly across many species of 
pathogens, such as between members of the Enterobacteriaceae, where 
the RP1 plasmid is transmissible between strains of P.  aeruginosa, 
E.  coli, and Proteus mirabilis. The sharing of resistance genes and 
rapid reproduction rate compressed Darwinian evolution, and led to 
a race between the emergence of resistant pathogens and the human 
need for miracle cures (Levy, 1982; Ventola, 2015a and 2015b).
The dispersal of AMR bacteria across human communities and 
globally occurs as for infectious diseases, i.e. by direct contact person 
to person, from animal to person (by scratches or bites) and vertically 
from mother to unborn child. In addition, insects such as mosquitoes, 
midges, fleas, lice, and ticks can act as vectors. The bacterium Borrelia 
burgdorferi, which causes Lyme disease, is transmitted by ticks of the 
genus Ixodes. Certain Borrelia strains express resistance to erythro-
mycin (Terekhova et  al., 2002). Members of the genus Rickettsia 
are obligate intracellular parasitic bacteria that grow directly within 
the cytoplasm of the eukaryotic host cell. Transmitted by lice of 
the genus Pediculus, Rickettsia prowazekii is the causative agent of 
epidemic typhus. A common site for rickettsial rifampin resistance 
mutations lies within the R. prowazekii rpoB gene, which codes for 
the β subunit of DNA-dependent RNA polymerase. Mutants which 
exhibit a single substitution of arginine for lysine at residue 546 
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carry rifampicin resistance. This mutation falls within a region of the 
rickettsial protein that corresponds to the rifampin resistance region 
of E. coli (Rachek et al., 2000).
Food contamination can allow bacteria to spread to many people 
from a single source, i.e. E. coli, Salmonella, or AMR bacteria. Non-
typhoidal Salmonella spp., Campylobacter spp., and E.  coli 0157 
are all listed as causing foodborne illnesses between 2000 and 2008 
in a CDC report (www.cdc.gov/foodborneburden). Iweriebor et al. 
(2015a) recorded multiple antibiotic resistances among E. coli 0157, 
in faeces of dairy cattle farms. Finally, AMR bacteria can also be 
transmitted by indirect contact, where the bacteria persist on an 
inanimate object, such as a door handle, liable to be touched by 
many individuals. Perhaps the ultimate form of transmission of 
AMR bacteria is via recent inventions, particularly global travel by 
aircraft. More than 1 billion people travel by air each year, and the 
greatest concern for global health is the ability of an individual with 
a contagious illness to travel to virtually any part of the world within 
24 h. Worth noting was the delay in the spread of influenza by the 
decrease in air travel, following the attacks of 11 September 2001 
( Mangili and Gendreau, 2005; Pavia, 2007). Arcilla et  al. (2017) 
reported that the acquisition and spread of E. coli and Klebsiella, 
which produce enzymes called extended-spectrum β-lactamases 
(ESBLs), during and after international travel, were substantial and 
worrisome. Strains carrying ESBLs are resistant to many penicillin 
and cephalosporin antibiotics. Travellers to areas with a high risk of 
acquisition of these strains should be viewed as potential carriers for 
up to 12 months after return (Arcilla et al., 2017).
The Antibiotic Paradox
However, the greatest complicating factor of the modern era has 
been the widespread and sometimes indiscriminate misuse and overuse 
of antibiotics. ‘The antibiotic paradox’ describes the premise that the 
misuse of antibiotics destroys their curative powers (Polly, 1993; Toner, 
2005) or ‘How miracle drugs are destroying the miracle’ (Levy, 2002). 
Prescribed initially when there was little option, antibiotics became 
overprescribed both for medicinal and veterinary use (Mateu and 
Martin, 2001), so imposing selective pressure on formerly sensitive 
bacteria to acquire resistance. The ever increasing demand for animal 
protein and consequential intensification of food animal production 
has led to greater use of antibiotics, since they were first introduced 
as growth promoters (Dibner and Richards, 2005; Anonye, 2016). 
Globally, the livestock sector is divided between developed and 
developing countries: total meat production tripled between 1980 and 
2002, from 45 to 134 million tons. Much of this growth accompanied 
the rapid economic growth of developing countries, particularly in 
East Asia, revolving around poultry and pigs. Overall, livestock 
production and merchandizing in industrialized countries account for 
53 per cent of agricultural GDP (Thornton, 2010).
The growth promoter effect of antibiotics was discovered in 
the 1940s when it was noted that animals fed dried mycelia of 
Streptomyces aureofaciens (containing chlortetracycline residues) 
improved their growth (Castanon, 2007). These beneficial effects 
were reported in poultry and swine between 1946 and 1950. The 
mechanism of action is related to interactions with the animals’ 
intestinal flora (Dibner and Richards, 2005; Niewold, 2007), but 
by 1951, there were reports of resistance following experimental 
feeding of turkeys with streptomycin. This was followed by reports 
of an association of resistance to tetracycline, when growth-
promoting levels of this antibiotic were fed to chickens (Dibner 
and Richards, 2005). Avoparcin is a glycopeptide antibiotic that 
was widely used in Europe as a feed additive or antibiotic growth 
promoter (AGP) from the 1970s to 1990s. A similar glycopeptide, 
vancomycin, became more widely used in the human population 
from the 1980s (Levine, 2006). In the mid-1990s, as VRE began to 
emerge, researchers in Denmark were documenting an association 
between avoparcin use in pigs and poultry with a prevalence of 
faecal carriage of VRE in animals on exposed farms (Bager et al., 
1997). Other European research recorded VRE in meat and in faeces 
of people in the farming community. The issue of VRE contributed 
to a growing sense of crisis concerning the use of AGPs and to calls 
for greater scrutiny or restrictions on antimicrobial use in animals, 
especially AGPs. In 1995, Denmark banned the use of avoparcin as 
a feed additive, which was followed by the voluntary withdrawal of 
all AGPs by the pig and poultry industries in Denmark. By 2005, all 
feed additives containing antibiotics, many of which were in classes 
used in humans, were banned across Europe (Casewell et al., 2003; 
Keen and Montforts, 2012).
The earliest concerns about the development of antibiotic 
resistance in human pathogens and recommendations to ban sub-
therapeutic use in animal feeds were discussed by Swann, in a report 
to the UK parliament in 1969 (Swann, 1969). The entry of resistant 
pathogens to the human food chain, and their subsequent transfer 
from animal to man by the consumption of contaminated food, is 
illustrated by Salmonella enterica, associated with poultry and poultry 
meat products. The estimated total cost for non-typhoidal Salmonella 
is in excess of $14 billion per year in the USA alone. Over 40 000 
cases of non-typhoidal foodborne salmonellosis are confirmed 
annually, with an estimated 1 million cases not being reported (Cosby 
et al., 2015). The Food and Agriculture Organization (FAO) Animal 
Production and Health working paper ‘Mapping Supply and Demand 
for Animal-Source Foods to 2030’ reported in 2011 that agricultural 
production would have to increase by 70 per cent (nearly 100 per 
cent in developing countries) by 2050 to cope with a 40 per cent 
increase in global population. This would include an additional billion 
tonnes of cereals and 200 million tonnes of animal-derived protein, 
per annum, as compared to production in 2005/07. The report notes 
that there are public health implications of further intensification of 
livestock production: the rapid spread of infectious diseases (such as 
the pandemic H1N1 influenza A virus) demonstrating the magnitude 
of problems arising from the emergence of novel diseases at the animal-
human-ecosystems interface (FAO, 2011). In 2010, over 63 000 tons 
of antibiotics were consumed by livestock globally, a figure which 
is projected to rise by 67 per cent by 2030, and nearly double in 
Brazil, Russia, India, China, and South Africa (Van Boeckel et  al., 
2015). Antibiotic-resistant bacteria can be transmitted to humans 
through direct contact with livestock, through the food chain and the 
wastewater from farms, hospitals, and pharmaceutical plants. In 2011, 
the CDC reported that AMR was increasing the economic burden on 
the entire American healthcare system, to the sum of $20 billion a year 
in excess costs. An additional $35 billion can be attributed to societal 
costs, and more than 8 million additional days spent in hospitals.
The Antibiotic Discovery Void
Since the advent of antibiotics, research and development efforts 
have provided an ongoing stream of novel drugs needed to treat the 
bacteria that had become resistant to the older antibiotics. However, 
in 2011, Silver reported that the timeline of dates of discovery of dis-
tinct classes of antibiotics showed that there had been no successful 
discovery of any new class since 1987 (Silver, 2011). The latest 
registered representatives of novel antibacterial classes, linezolid, 




























































































































































Figure 1. A chart showing time from antibiotic introduction to first report of clinical resistance. 
daptomycin, and the topical agent retapamulin, were indeed 
introduced in 2000, 2003, and 2007, respectively, but these chemical 
classes (oxazolidinones, acid lipopeptides, and pleuromutilins) were 
first reported (or patented) in 1978, 1987, and 1952, respectively. 
A timeline of dates of discovery of distinct classes of antibacterials 
(as opposed to dates of introduction) illustrates that there have been 
no (as yet) successful discoveries of novel agents since 1987. There is 
a discovery void of unknown extent rather than a gap (see Table 2). 
Coates et al. (2011) noted that between 1940 and 1962, more than 
20 new classes of antibiotics were marketed, and that to return to a 
situation in which there were enough antibiotics to cope with inev-
itable ongoing emergence of resistance, governments would have to 
introduce legislation and provide industry and academia with real 
incentives. Due to this void pharmaceutical companies have been 
withdrawing from research in this area, despite the recognition of 
the continuing need for new antibacterials to combat the rise of 
resistant organisms (Silver, 2011). According to Ventola writing in 
2015, some 15 of the 18 largest pharmaceutical companies have 
abandoned the antibiotic field. Mergers between pharmaceutical 
companies substantially reduced the number and diversity of re-
search teams, and research conducted by academia was scaled back 
due to funding cuts following the economic crisis (Ventola, 2015b).
The reasons why there now exists a void in the development of 
novel antibiotics are complex. Drugs used to treat chronic illnesses 
such as diabetes and hypertension offer a much greater potential re-
turn on investment for the larger pharmaceutical companies. Research 
by the pharmaceutical industry (‘Big Pharma’) is concentrated on 
drugs likely to make annual global sales in excess of several billion 
US dollars. In recent years, peak antibiotic sales are in the region of 
$500 million to US$ 1 billion (World Economic Forum, 2013). On 
average, pharmaceutical companies spend $5 billion on research and 
testing for each new drug they bring to the market; some 80 per cent 
of drugs produced fail in safety and efficacy testing. In the USA, in 
July 2012, Congress passed the ‘Generating Antibiotic Incentives Now 
(GAIN) Act’. According to the US Food and Drug Administration 
(USFDA), this act highlighted and listed pathogens with the poten-
tial to pose a serious threat to public health, such as C. difficile and 
multidrug-resistant tuberculosis. The GAIN act carried incentives 
such as granting an additional 5  years exclusivity at the time of 
product approval for products granted a Qualified Infectious Disease 
Product (QDIP) designation. There were to be priority reviews for 
marketing applications for products that carried a QDIP designation, 
and products granted QDIP designation were to be eligible for fast 
track designation. The FDA was to review and update at least three 
guidances per year for the development of antibacterial and antifungal 
drugs, and publish a guidance on pathogen-focused antibacterial drug 
development (USFDA, 2013). Other classes of drugs are not beset 
by resistance issues and would have rapid global coverage, whereas 
antibiotics would be more restricted, last-resort treatments, resulting 
in much lower sales. The smaller companies cannot afford the costs 
of the complex requirements for clinical trials, so compromising the 
development of potential new agents (Piddock, 2012).
Why Is Developing New Antibiotics Becoming 
Less Attractive to Big Pharma?
The evidence-base has demonstrated that more and more species 
and genera of bacteria are becoming more resistance to several 
existing antibiotics. So, hypothetically, this should generate a de-
mand for the development of new antibiotics to combat these 
now-resistant bacteria. While this is indeed the case, response from 
antibiotic manufacturers in Big Pharma has been slow due to the 
relatively unattractive business scenario that this presents. Figure 1 
shows historically the time taken for bacteria to generate resistance 
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to newly introduced antibiotics. Of the 15 antibiotics listed in 
Figure 1, the mean duration to resistance is 6.9  years. Given the 
time taken to develop a new antibiotic through innovation relating 
to the molecular toxicology screenings and then Phase I, II, and 
III clinical trials, accompanied by a finite patent life, the addition 
of biological resistance makes financial investment into novel 
antibiotics less attractive, even though there is a huge demand in the 
clinical marketplace.
Conclusion
AMR has now emerged as a global threat to human and veterinary 
public health. Prudent employment of the existing arsenal of available 
and licenced antibiotics needs to be emphasized and schemes 
adopted including antimicrobial stewardship codes of conduct, in 
order to extend the usefulness and efficacy of such antibiotic agents 
for generations. New economic incentives need to be developed to 
encourage investment into novel antibiotics by the pharmaceutical 
industry, so that society will have effective tools to combat infectious 
diseases for generations to come.
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